179 results on '"Tyrosine -- Product development"'
Search Results
2. MedStar Georgetown University Hospital Researcher Adds New Data to Research in Chronic Myeloid Leukemia (Global Trial Representation and Availability of Tyrosine Kinase Inhibitors for Treatment of Chronic Myeloid Leukemia)
3. Study Results from University of Sydney Broaden Understanding of Receptor Protein-Tyrosine Kinases [Randomised, multicentre, placebo-controlled trial of fenofibrate for treatment of diabetic macular oedema with economic evaluation (FORTE study): ...]
4. Patritumab Deruxtecan Demonstrated Statistically Significant Improvement in Progression-Free Survival Versus Doublet Chemotherapy in Patients with Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer in HERTHENA-Lung02 Phase 3 Trial
5. Studies from Sichuan University Yield New Information about Clinical Trials and Studies (Safety, Pharmacokinetics and Pharmacodynamics of Hwh486 Capsules In Healthy Adults: a Randomized, Double-blind, Placebo-controlled, Phase I Dose-escalation ...)
6. Study Findings on Chronic Myeloid Leukemia Reported by a Researcher at University of North Carolina UNC Eshelman School of Pharmacy (Evaluation of real-world versus clinical trial outcomes of tyrosine kinase inhibitor therapy for chronic ...)
7. Exelixis initiates STELLAR-305 phase 2/3 pivotal trial of zanzalintinib in combo with pembrolizumab in patients with previously untreated recurrent or metastatic SCCHN
8. Exelixis, Arcus Biosciences enter clinical trial collaboration to evaluate zanzalintinib in combo with AB521 in patients with advanced RCC
9. Hutchmed begins phase I study of novel SHP2 inhibitor HMPL-415 for advanced malignant solid tumours in China
10. Novartis Phase III data confirm sustained efficacy and long-term safety of oral remibrutinib in chronic spontaneous urticaria
11. Ashvattha Therapeutics to Present Preclinical Data at the CMSC and SNMMI Annual Meetings
12. Tyrosine Kinase 2 Inhibitors Pipeline Assessment, 2024 Updates | In-depth Insights into the Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Clinical Trials | Galapagos, Haisco Pharmaceutic
13. Reports Outline Psoriasis Study Findings from Oregon Medical Research Center (Deucravacitinib, a Selective, Allosteric Tyrosine Kinase 2 Inhibitor, In Scalp Psoriasis: a Subset Analysis of Two Phase 3 Randomized Trials In Plaque Psoriasis)
14. Takeda announces phase 2b trial of TAK-279 to treat moderate-to-severe plaque psoriasis meets primary and secondary endpoints
15. Astellas and BMT CTN's phase 3 MORPHO trial of gilteritinib fails to meet its primary endpoint
16. ProfoundBio Announces First Patient Dosed in Phase 1|2 Clinical Trial of PRO1107, a Protein Tyrosine Kinase 7 (PTK7)-Targeted Antibody-Drug Conjugate Incorporating a Novel, Proprietary Hydrophilic MMAE-Based Linker-Drug
17. ProfoundBio Announces First Patient Dosed in Phase 1/2 Clinical Trial of PRO1107, a Protein Tyrosine Kinase 7 (PTK7)-Targeted Antibody-Drug Conjugate Incorporating a Novel, Proprietary Hydrophilic MMAE-Based Linker-Drug
18. Inhibikase Therapeutics Announces Publication Highlighting Results from its Phase 1 Studies with Risvodetinib
19. American neurologists are anxiously anticipating potential oral treatments for multiple sclerosis using promising Bruton's tyrosine kinase inhibitors. However, recent trial results could dampen their initial enthusiasm
20. U.S. Neurologists Eagerly Await Promising Oral Bruton's Tyrosine Kinase Inhibitors in Multiple Sclerosis Treatment Pipeline, Though Recent Trial Readouts Might Hamper Initial Excitement
21. University of Bordeaux Researcher Yields New Findings on Chronic Myeloid Leukemia [European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in Chronic Myeloid Leukemia: Final Analysis and Novel Prognostic Factors for Treatment-Free Remission]
22. Avistone Announces Phase II Results for Vebreltinib, a c-Met Tyrosine Kinase Inhibitor at the European Society for Clinical Oncology Congress
23. Biomea Fusion Announces First Patient Dosed with Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia in Phase I Clinical Trial (COVALENT-103)
24. Takeda Announces Positive Topline Results from Phase 2b Study Evaluating TAK-279, a Highly Selective Oral TYK2 Inhibitor, for the Treatment of Active Psoriatic Arthritis
25. US FDA clears Inmagene Biopharma's IND for third generation BTK inhibitor, IMG-004 to treat immunological diseases
26. Angion Biomedica gets US FDA clearance to initiate phase 1b study of ANG-3070 in patients with IPF
27. Ashvattha Therapeutics Presents Promising Preclinical Data on New Dendranib Nanomedicine Candidate ASH41020 at the 16th International Society of Neuroimmunology Congress (ISNI)
28. HUTCHMED Initiates Phase I Study of its novel SHP2 inhibitor HMPL-415 for Advanced Malignant Solid Tumors in China
29. Global Bcr Abl Tyrosine Kinase Inhibitor Drug Market, Drug Price, Sales & Clinical Trials Insight 2029
30. Nurix Therapeutics Presents Data from Studies of Its Targeted Protein Degraders in B Cell Malignancies and Initiates Expansion of NX-2127 Phase 1b Trial in Diffuse Large B Cell Lymphoma and Mantle Cell Lymphoma Indications
31. Yamo Pharma begins patient enrollment in phase 2 study of L1-79 in autism spectrum disorder
32. Recent Findings from Okayama University Provides New Insights into Non-Small Cell Lung Cancer (A Randomized Phase Ii Study of Afatinib Alone or Combined With Bevacizumab for Treating Chemo-na & Iuml;ve Patients With Non-small Cell Lung Cancer ...)
33. InnoCare Announces First Subject Dosed in Clinical Trial of ICP-332
34. Bridge Biotherapeutics Releases Updated Preclinical Data for BBT-207 at the AACR Annual Meeting
35. Brutons Tyrosine Kinase (BTK) Inhibitors - Emerging and Marketed Products Analysis | Clinical Trials Evaluation, Latest FDA, EMA, and PMDA Approvals, Competitive Landscape, and Key Companies
36. Splenic Tyrosine Kinase SYK Inhibitors Market Clinical Trials Companies Insight
37. Splenic Tyrosine Kinase SYK Inhibitors Market Clinical Trials Companies Insight
38. Splenic Tyrosine Kinase SYK Inhibitors Market Clinical Trials Companies Insight
39. Astellas and BMT CTN Announce Topline Results from Phase 3 MORPHO Trial of Gilteritinib
40. Study Data from University of California San Francisco (UCSF) Provide New Insights into Type 1 Diabetes (Imatinib Therapy for Patients With Recent-onset Type 1 Diabetes: a Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 2 Trial)
41. Cabometyx(R) in combination with nivolumab shows durable survival benefits at over three-years' follow-up in first-line advanced renal cell carcinoma
42. Study Findings on Chronic Myeloid Leukemia Are Outlined in Reports from University Hospital (Successful Tyrosine Kinase Inhibitor Discontinuation Outside Clinical Trials - Data From the Population-based Swedish Chronic Myeloid Leukaemia Registry)
43. Biomea Fusion Presents at the 2022 ASH Annual Meeting Preclinical Data on BMF-500 Supporting its Potential as the Most Potent and Selective FLT3 Inhibitor to Date
44. Puma Biotech announces interim results from phase II SUMMIT trial of neratinib for EGFR exon 18 mutated, metastatic NSCLC
45. Investigators at Center Leon Berard Report Findings in Adverse Drug Reactions [Ripretinib In Patients With Advanced Gastrointestinal Stromal Tumours (Invictus): a Double-blind, Randomised, Placebo-controlled, Phase 3 Trial]
46. Research Results from Cancer Hospital Update Knowledge of Carcinomas (Anlotinib for Patients With Metastatic Renal Cell Carcinoma Previously Treated With One Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor: A Phase 2 Trial)
47. New Findings from Gottingen University Medical Center Yields New Data on Tyrosine Kinase Inhibitors [Impact of preoperative treatment on the CINSARC prognostic signature: translational research results from a phase 1 trial of the German ...]
48. Researchers at University Hospital of Canarias Target Tyrosine Kinase Inhibitors (Pazopanib for treatment of typical solitary fibrous tumours: a multicentre, single-arm, phase 2 trial)
49. Medical University of Bialystok Researchers Reveal New Findings on Amino Acids [Bruton's Tyrosine Kinase Inhibitors (BTKIs): Review of Preclinical Studies and Evaluation of Clinical Trials]
50. Jinan Central Hospital Affiliated to Shandong First Medical University Reports Findings in Clinical Trials and Studies (Effect of Dietary Intake on the Pharmacokinetics of the Multitargeted Receptor Tyrosine Kinase Inhibitor Famitinib: Results ...)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.